Mar 15, 2018 20:01 pm UTC| Business
Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% BELBUCA prescription...
Mar 15, 2018 20:01 pm UTC| Business
Revenue for the Quarter Grew 40% over the Comparable Prior Year Quarter and 21% for the Full Year, Raising $30 Million in Equity and Significantly Improving Balance Sheet and Cash Position, Reimbursement Continued to Grow...
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
Mar 15, 2018 20:01 pm UTC| Business
YARDLEY, Pa., March 15, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging...
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Mar 15, 2018 20:01 pm UTC| Business
Conference Call Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and...
Rockwell Medical Reports Fourth Quarter and Year End 2017 Results
Mar 15, 2018 20:01 pm UTC| Business
Conference call at 4:30 p.m. EDT today WIXOM, Mich., March 15, 2018 -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 15, 2018 20:01 pm UTC| Business
STAMFORD, Conn., March 15, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively...
CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update
Mar 15, 2018 20:01 pm UTC| Business
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., March 15, 2018 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and...